A Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries
A legfontosabb adatok
- Ki végzi
- FrontAce Scientific Co., Ltd
- Hol
- Beijing, Chengdu, Chongqing, Hangzhou, Luzhou, Nanjing, Nantong, Shanghai, Shijiazhuang, Wuhan és Zhengzhou (Kína)Mind a 12 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 240 fő, tervezett
- Kezdés
- 2024. jún. 4.
- Várható befejezés
- 2026. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Sperstent® peripheral spot stent system
- Everflex® self-expanding peripheral stent system
- A regiszteradat frissítve
- 2024. augusztus 6.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with narrowed or blocked leg arteries in the thigh or behind the knee. They must still have narrowing or a tear in the artery wall after balloon treatment. The trial compares two stents (small metal tubes that hold the artery open).
- Életkor
- 18 to 85 years
- Nem
- All sexes
- A betegség stádiuma
- Peripheral artery disease with symptoms of Rutherford class 2 to 5, in the superficial femoral artery or the upper popliteal artery. Narrowing of at least 70%, or a full blockage shorter than 150mm. Total lesion length 50mm to 250mm, vessel size 3 mm to 7.5 mm. Expected to live more than 1 year.
- Korábbi kezelés
- After balloon treatment with a DCB, more than 30% narrowing or at least one tear in the artery wall must remain. People cannot join if they had bypass or other open surgery on the artery, or a stent already in it.
A részvétel fő kizáró okai
- Serum creatinine >2.5mg/dl (221 µmol/L), or long-term haemodialysis or peritoneal dialysis
- Heart attack or stroke with symptoms within 3 months
- Severe bleeding or clotting disorder, or a past or planned organ transplant
- Allergy to contrast agents, nickel or titanium, heparin, aspirin, clopidogrel or anaesthetics
- Pregnancy, breastfeeding, or plans for a family within 1 year
A regiszter feltételei, szó szerint
Mind a 30 feltétel megnézéseKevesebb
Ki vehet részt
- Age 18-85 years old, male or female
- The target lesion is located in the superficial femoral artery or the proximal popliteal artery
- Peripheral arterial stenosis or occlusive disease with symptoms consistent with the Rutherford classification 2 to 5
- Estimated life expectancy >1 year
- Subject has been informed of and understands the nature of the study and provides signed informed consent to participate in the study; Angiographic Inclusion Criteria:
- Stenosis rate ≥70% under DSA by visual estimate, or 100% occluded lesion with a total lesion length less than 150mm (by visual estimate)
- Reference vessel diameter is between 3 mm and 7.5 mm, 50mm≤Total cumulative length of target lesions≤250mm; (In the case of bilimb lesions, a single target lesion with one limb meeting the protocol criteria is selected by the investigator; More than 2cm between lesions are considered as 2 lesions)
- After PTA treatment by DCB, there exists residual lesions, such as the target lesion has over 30% residual DS and/or presence of at least one post-PTA dissection (Type A-F) (by visual estimate)
- Patients with unobstructed inflow tract or successfully treated, visual residual stenosis ≤50%
- Angiography showed at least one outflow tract was unobstructed at the distal end (Stenosis degree ≤70% before intervention)
Ki nem vehet részt
- Target vessel had undergone open surgery such as bypass surgery or the target lesion is in-stent restenosis
- A history of major organ failure or other serious illness (including severe coronary heart disease, severe cardiac insufficiency, severe neurosis, or mental illness); Have received or plan organ transplantation, severe gastrointestinal bleeding)
- Myocardial infarction or symptomatic stroke occurred within 3 months prior to enrollment
- Thrombolysis of target vessel within 72 hours before surgery, did not completely dissolve the thrombus
- Endovascular or surgical procedures are performed on the target limb within 30 days before or 30 days after surgery
- Participating in clinical trials of other medical devices or drugs
- During the procedure, the target lesions had received or were scheduled to receive volume reduction procedures such as cryogenic angioplasty, laser angioplasty, and percutaneous intracavity plaque gyrotomy;
- Severe coagulation disorder
- Patients with major vascular-related diseases, including acute lower extremity ischemia, active disseminated intravascular coagulation, thromboangiitis obliterans, deep vein thrombosis, and aneurysms of therapeutic lateral vessels (deep femur, superficial femur, or popliteal artery)
- Systemic infection or uncontrolled infection within the target limb
- Known allergy to contrast agents, nickel or titanium (Nitinol), heparin, aspirin, clopidogrel, anesthetics
- Failure of the guidewire to pass through the lesion;
- Acute vascular occlusion or acute or subacute thrombosis in the target lesion;
- Patients with serum creatinine >2.5mg/dl during screening or undergoing long-term hemodialysis or peritoneal dialysis
- Women who are pregnant or breast-feeding, or women of childbearing age who have family plans within 1 year
- Patients who are planning to have major lower limb amputations on the target side of the lesion
- The investigator considers the patient is not suitable for participation in the clinical trial; Angiographic Exclusion Criteria:
- The target lesion before stent implantation is thrombotic obliteration, which is not suitable for stent implantation;
- The target lesions were severely calcified and could not fully predilate; Or grade 4 calcification;
- Stent was implanted into the target vessel before enrollment
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 85 év között vagy?
Helyszínek itt: Kína
- Beijing Friendship Hospital, Capital Medical UniversityBeijing, KínaContact: Hai FengToborzás még nem indult
- Hospital of Chengdu University of TCMChengdu, KínaContact: Chunshui HeToborzás még nem indult
- The First Affiliated Hospital of Chongqing Medical UniversityChongqing, KínaContact: Yu ZhaoToborzás még nem indult
- The First Affiliated Hospital Zhejiang University School of MedicineHangzhou, KínaContact: Hongkun ZhangToborzás még nem indult
- The Affiliated Hospital of Southwest Medical UniversityLuzhou, KínaContact: Yong LiuToborzás még nem indult
- Nanjing Drum Tower hospitalNanjing, KínaContact: Min ZhouRésztvevőt keres
- Affiliated Hospital of Nantong UniversityNantong, KínaContact: Hui ZhaoToborzás még nem indult
- Renji Hospital Shanghai Jiao Tong University School of MedicineShanghai, KínaContact: Meng YeToborzás még nem indult
- Shanghai East HospitalShanghai, KínaContact: Xiang WangRésztvevőt keres
- The Second Hospital of Hebei Medical UniversityShijiazhuang, KínaContact: Wei BiToborzás még nem indult
- Liyuan Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, KínaContact: Zibo FengRésztvevőt keres
- First Affiliated Hospital of Zhengzhou UniversityZhengzhou, KínaContact: Zhen LiToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is a prospective, multi-center, randomized trial designed to investigate the efficacy and safety of Sperstent® peripheral spot stent system versus Everflex® self-expanding peripheral stent system in the endovascular treatment of post-balloon angioplasty (post-PTA) residual lesions including stenoses and/or dissections in femoral and proximal popliteal arteries.
A vizsgálat 2 csoportja
- Sperstent® peripheral spot stent systemA vizsgált kezelés
subjects using the Sperstent® peripheral spot stent system
- Everflex® self-expanding peripheral stent systemMár használt kezelés, összehasonlításként
subjects using the Everflex® self-expanding peripheral stent system
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Prospective, Multicenter and Randomized Controlled Trial to Evaluate the Efficacy and Safety of Sperstent® Peripheral Spot Stent System Used for the Residual Lesions After Percutaneous Transluminal Angioplasty of Femoropopliteal Arteries
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Illeszkedési kérdések
- Forrás: NCT06539689: ki vehet részt
- A regiszteradat frissítve
- 2024. augusztus 6.